|Articles|April 10, 2018
Shanghai HEP Pharma Signs Agreement with OmniComm Systems
Advertisement
Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
3
Is Artificial Intelligence Coming for Clinical Research?
4
FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
